David Allen Annis

This inventor holds 13 USPTO granted patents and 18 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Aileron Therapeutics, Inc., Alleron Therapeutics, Inc., Merck + Co., Inc.. Active years: 2008-2021.

USPTO Granted Patents = 13 (Patent Applications = 18)

% Patents Active = 30.8

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 3.9

ph-index = 8

Forward Citations = 206(Granted Patents)

Company Filing History:

11 out of 44

Aileron Therapeutics, Inc.

patents

1 out of 2

Alleron Therapeutics, Inc.

Years Active: 2008-2021

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11091522 - Peptidomimetic macrocycles and uses thereof (2021-08-17),

2. 10905739 - Peptidomimetic macrocycles and formulations thereof (2021-02-02),

3. 10471120 - Peptidomimetic macrocycles and uses thereof (2019-11-12),

4. 10253067 - Peptidomimetic macrocycles and uses thereof (2019-04-09),

5. 10059741 - Peptidomimetic macrocycles (2018-08-28),

6. 10022422 - Peptidomimetic macrocycles (2018-07-17),

7. 9458202 - Peptidomimetic macrocycles with improved properties (2016-10-04),

8. 9175047 - Peptidomimetic macrocycles (2015-11-03),

9. 9175045 - Peptidomimetic macrocycles (2015-11-03),

10. 8808694 - Therapeutic peptidomimetic macrocycles (2014-08-19),

11. 8524653 - Peptidomimetic macrocycles (2013-09-03),

12. 8399405 - Peptidomimetic macrocycles (2013-03-19),

13. 7449599 - Phenyl carboxamide compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease (2008-11-11),

Title: **David Allen Annis: Innovator in Peptidomimetic Macrocycles**

Introduction

David Allen Annis is a prominent inventor based in Cambridge, MA, known for his significant contributions to the field of pharmaceutical formulations and treatments, particularly involving peptidomimetic macrocycles. With 13 patents to his name, Annis continues to push the boundaries of innovation in medicinal chemistry and therapeutic applications.

Latest Patents

Among his latest patents, Annis has focused on the synthesis and application of peptidomimetic macrocycles for treating various conditions, including cancer. His patent titled "Peptidomimetic Macrocycles and Uses Thereof" outlines methods for utilizing these macrocycles in combination with additional pharmaceutically-active agents to enhance treatment efficacy. Another critical patent, "Peptidomimetic Macrocycles and Formulations Thereof," provides details on aqueous pharmaceutical formulations for parenteral administration. This formulation specifically targets MDM2 and/or MDMX proteins, offering potential therapeutic solutions for various diseases and disorders.

Career Highlights

David Allen Annis has contributed significantly to the pharmaceutical research landscape, particularly through his roles at Aileron Therapeutics, Inc. and Alleron Therapeutics, Inc. His work in these organizations has involved pioneering research and development in peptide-based therapies, reflecting his commitment to advancing medical science.

Collaborations

Annis has collaborated with notable professionals in the field, including Huw M. Nash and Tomi K. Sawyer. These partnerships have been crucial in driving his research forward and enhancing the impact of his inventions within the pharmaceutical industry.

Conclusion

David Allen Annis represents a vital figure in the innovation of pharmaceutical therapies, with his ongoing research delivering hope for improved treatment options. His extensive patent portfolio and collaborative approach highlight his dedication to advancing health through scientific discovery, marking him as an influential inventor in modern medicine.